Cholesterol lowering – proven or not?

Repatha

Just before I head off on holiday for a couple of weeks, I thought I should make a quick comment on the Repatha trial (PCSK9- inhibitor). I have written much about this new class of cholesterol lowering drugs, and I have been highly skeptical that they would have any benefits on cardiovascular disease. [Mainly on the basis that I don’t believe raised LDL causes CVD, and these drugs have one action – to lower LDL].

As many of you will be aware, the data from a clinical trial on Repatha has just been released. It was reported by the BBC thus

‘Huge advance’ in fighting world’s biggest killer.’

An innovative new drug can prevent heart attacks and strokes by cutting bad cholesterol to unprecedented levels, say doctors. The results of the large international trial on 27,000 patients means the drug could soon be used by millions.

The British Heart Foundation said the findings were a significant advance in fighting the biggest killer in the world. Around 15 million people die each year from heart attacks or stroke. Bad cholesterol is the villain in the heart world – it leads to blood vessels furring up, becoming easy to block which fatally starves the heart or brain of oxygen.

It is why millions of people take drugs called statins to reduce the amount of bad cholesterol . The new drug – evolocumab – changes the way the liver works to also cut bad cholesterol. “It is much more effective than statins,” said Prof Peter Sever, from Imperial College London.

He organised the bit of the trial taking place in the UK with funding from the drug company Amgen. Prof Sever told the BBC News website: “The end result was cholesterol levels came down and down and down and we’ve seen cholesterol levels lower than we have ever seen before in the practice of medicine.”

And so on, and so forth. So, the Repatha trial was a huge success. Obviously, it certainly lowered LDL to levels never seen before. Or, maybe it was not quite such a huge success. Michel de Logeril, a professor of cardiology in France – who set up and ran the famous, and successful, Lyon Heart Study sent me this comment.

‘This is just junk science.

The calculated follow-up duration required to test the primary hypothesis was 4 years as written by the authors themselves (but only in the second last paragraph before the end of discussion…) but the actual median duration of follow-up has been 2.2 years; it is thus a biased trial (a similar bias as in JUPITER: 1.9 years instead of 4 years): early stop!

In addition, contrary to the misleading claims in the medias, there was no effect on both total [444 deaths with evolocumab vs. 426 with placebo] and cardiovascular [251 vs. 240] mortality; which is not unexpected with a so short a follow-up.

They pretend that they are differences for non-fatal AMI and stroke but there is no difference in AMI and stroke mortality… Very strange… It would be critical to get access to the raw clinical data to verify the clinical history of each case in both groups.

Well, in my opinion and given the present state of consciousness among US doctors, FOURIER is a flop!

Best

Michel’

What he is saying, is that there was a reported reduction in non-fatal heart attacks and stroke. And less need for revascularization procedures e.g. PCI/stents. As you may gather Professor de Logeril would like to see the raw data to verify this. There is very little chance that this will be made available.

Anyway, that was the upside.

The downside is when you look at cardiovascular deaths.

  • The total number of deaths from cardiovascular disease in the Repatha group was 251
  • The total number of deaths from cardiovascular disease in the placebo group was 240
  • So, 11 more people died of cardiovascular disease in the Repatha group

The overall mortality data

  • The total number of, overall, deaths in the Repatha group was 444
  • The total number of, overall, deaths in the placebo group was 426
  • So, there were 18 more deaths in those taking Repatha.

The differences here are not large enough to be statistically significant. However, there were more, not less, deaths in the Repatha group, and more, not less, CV deaths. This study was also terminated early, which is extremely bad news for any clinical trial, and casts enormous doubt on any findings. It was supposed to last four years, but was stopped at 2.2 years. Why? Were the mortality curves heading rapidly in the wrong direction.

Alongside this, should be set the knowledge the Pfizer also had a PCSK9-inhibitor undergoing clinical trials, and they pulled the plug, right in the middle of it all.

Pfizer Ends Development Of Its PCSK9 Inhibitor

‘November 1, 2016 by Larry Husten

Immune issues and diminishing efficacy doomed the new drug.

Pfizer announced on Tuesday that it was discontinuing development of bococizumab, its cholesterol-lowering PCSK9 inhibitor under development.

“The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders,” the company explained.

Pfizer said that it would halt two very large ongoing cardiovascular outcome studies with bococizumab, the 17,000 patient SPIRE 1 trial and the 10,000 patient SPIRE 2 trial. The trials were fully enrolled.’

Pulling the plug when 27,000 patients had been fully enrolled. What on earth did they see. Something more than slightly worrying. I guess we will never really know, but that is one hell of a write off.

It is also interesting to note that Amgen – the company selling Repatha, has announced that:

‘Amgen to refund cholesterol drug if patients suffer heart attack

Pledge aims to convince insurers to pay for $14,000-a-year medicine.2

As reported in the Financial Times.

This is a big vote of confidence … not! I think, perhaps, we are looking at a doomed drug. Probably a doomed class of drugs. Has the cholesterol hypothesis been verified, or contradicted? I know I am biased, but I know what I think.

1: http://cardiobrief.org/2016/11/01/pfizers-ends-development-of-its-pcsk9-inhibitor/

2: https://www.ft.com/content/34154cdc-0a86-11e7-ac5a-903b21361b43

144 thoughts on “Cholesterol lowering – proven or not?

      1. Stephen T

        Pharma wants people alive and taking medicine for many years. Those are the dream drugs for them. Killing us prematurely makes no sense for them and takes suspicion of these profit driven people beyond the facts. I don’t think they mind harming us, because they’ll probably find another drug to treat us.

    1. xtronics

      What is particularly telling:

      No mention of it’s effect on Lp(a) – I think I can guess why.

      No mention of it’s effect on oxLDL – I think I can guess why.

      If you read the paper – look at the comments – that paper should never have been published in the form it is in.

      Reply
    1. stcrim

      The only people stressed out about Trump are those who want America to fail. They are the people who desire Socialism even though it is an experiment that has repeatedly failed. There is a lag time between the stress and the event so I would guess there will be an increase in CVD deaths during Trumps watch in the same way there was in the 1950’s following WWII. How ever they will be a result of the 8 years before the Trump watch. The U.S. was on the road to destruction – now most Americans have hope. Most of what you see in the media doesn’t even hint at the truth…

      Reply
      1. Eric

        Socialism has been and still is an intellectual laziness predominantly found in the US to disqualify any fact or argument one does not like.

        The article may not have covered all its bases, but a change from 50 to 80% from summer of 2016 to now is a significant change. Also, he who must not be named has a way of being omnipresent and of bending reality to the tune of his tweets. Never realized Joanne K. Rowling was that prescient about politics…

    2. Dr. Göran Sjöberg

      Eric,

      Well this Trump issue is a little bit disputable to my opinion.

      Being “left” all my life I still find this guy “interesting” from the health perspective. He has confronted Big Pharma on the vaccines and not least accused main stream media, MSM, as “liars”. I am just fed upp with all the Big Pharma lies I find in MSM so here I am fully on his side.

      Reply
      1. Eric

        MSM= methyl sulphonyle methane?

        He may have delivered a needle prick (by his standards) on vaccination, questionable as his position may be, but he’s letting Paul Ryan and his irk have their go on health insurance contrary to his election promises.

  1. Gay Corran

    Thank you again, Dr K. I wonder what convinces newspapers to interpret the trials thus? Oh, silly me they need the advertising from the pharma companies! Have a good holiday and please don’t get pneumonia on your return.

    Reply
  2. Franklin

    Sounds like the Vytorin results. Much lower cholesterol, same CVD results. IMPROVE-IT trail Quote: “There was no reduction in all-cause or CV mortality with simvastatin+ezetimibe, though there was a reduction in MI and stroke”

    Reply
    1. Andy S

      Hi Franklin: Vytorin will give you a choice on what you want to be on your death certificate as a cause of death.

      Reply
  3. mikecawdery

    Dr.Kendrick
    ‘This is just junk science.

    Another blistering attack on a highly biased and data manipulated study. This is what makes me wonder at the cognitive levels of so-called professors. May be the statin effect on the brain is demonstrated. Frankly, should I be hospitalized, may be it would be better to arrive DOA rather the be subject to some weird ideas called modern medicine.

    The following papers can be downloaded in full. Risk getting diabetes on the one hand or, as individuals, take new drugs with the near certainty that you will NOT BENEFIT.

    http://www.nature.com/articles/srep39982

    Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis

    http://www.nejm.org/doi/full/10.1056/NEJMoa1615664

    Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

    Zoe Harcombe has reported on both.. Another damning report.

    I despair

    Reply
    1. Tom Welsh

      “This is what makes me wonder at the cognitive levels of so-called professors”.

      I suspect you may be measuring the wrong variable. Have you looked at their bank-account levels?

      Reply
    2. David Bailey

      This sentence amused me:

      ““The end result was cholesterol levels came down and down and down and we’ve seen cholesterol levels lower than we have ever seen before in the practice of medicine.”

      Since cholesterol is required by the body, how can that result be considered a success? At some point it is surely clear that low cholesterol would starve the brain of a vital raw material.

      @Malcolm Was absolutely no reason given for stopping the trial? Are they claiming that it would be unethical to withhold this wonderful treatment from the placebo group – what other reason could there be other than a serious side effect?

      I guess I would be classed as ‘statin intolerant’, but I’m going nowhere near PCSK9 inhibitors!

      Reply
      1. Andy S

        David, the focus is on winning the war on bad cholesterol , that is why the results are astounding. The scientists have almost eliminated bad cholesterol. Good cholesterol will then replace bad cholesterol. Health issues will be addressed when this is accomplished. Don’t give up hope, the scientists are regrouping for the final assault on bad cholesterol. Stopping the trial was a strategic
        diversion tactic to confuse the enemy. That is the nature of war.

  4. robert lipp

    Berberine
    Has anybody looked up the natural product (used by the Chinese for millennia) Berberine?
    It apparently does the same thing in the liver as PCSK9.
    Why spend $billions developing a product that probably has minimal value at best for which there is a cheap natural product?

    Reply
    1. Gary Rees

      Robert, I tried Berberine for a while, It did wonders for LDL and helped with Blood glucose. One of the botanicals that contains berberine grows in my back 40. So its perfect except that blood tests showed damage to kidneys(?) . The Doctor said that weightlifters and statin users show
      elevated levels . I have forgotten the name of the “stuff”.
      Did the PCSK9 inhibitor trial and developed an injection site injection urticarial as big as a dinner plate. I got talked into the trial and promised pieces of silver.
      I knew better.

      Reply
    2. mikecawdery

      Why spend $billions developing a product that probably has minimal value at best for which there is a cheap natural product?

      Simple – There is no perception of profit for the “cheap natural product”. Big Pharma and the medical industry are only interested in patents and the consequent huge profits and status.

      Another question is why is most money spent on “curing” rather than prevention excluding vaccines. With regards to vaccines why did the US government protect Big Pharma by banning any legal action against them for injury compensation for “safe and effective vaccines. Instead the US Govt. set its own system of compensation for vaccine injuries, thus protecting Big Pharma from class actions caused by their “safe and effective vaccines”? But then many powerful politicians are directly involved in Big Pharma.

      Reply
      1. Andy S

        Stephen: we know it doesn’t help, the sub-conscious “bad cholesterol phobia” still exists and we also have to please the doctor.

    3. Bill

      Why attempt to lower cholesterol at all? There’s no advantage, in fact, lowering cholesterol to unprecedented levels will created illness on an epidemic scale. The only beneficiaries of this will
      be; ah yes, the Pharma industries.

      Reply
      1. Andy S

        Bill: What do you suggest we do with the “bad” cholesterol? A doctor will not agree with your thinking.

    4. robert lipp

      Why spend $billions developing a product that probably has minimal value at best for which there is a cheap natural product?

      I just loved the irony – smile

      Reply
  5. Cary Blackburn

    Presumably the hypothesis that Cholesterol causes Heart Attacks is a now a given so all these trials have to prove is that the drug in question lowers Cholesterol more than the previous ones therefore it is more effective at reducing CVD. The fact that more peopled died using the drug can therefore be ignored. To all my many friends currently on Statins: be afraid, very afraid.

    Reply
  6. Sue Knight

    Hello Dr Kendrick, My God, what is the matter with this Prof. from Imperial College London, The British Heart Foundation, The NHS, our entire health system (bar the blessed few)? Obviously this is not a question I need any answer on because I know. It’s just the elephant in the room, and he’s taking up too much space and causing a great deal of mess!
    Have a good break and I look forward to your next blog.

    Reply
  7. Gaetan

    This is simply disgusting that anyone would claim any benefits from that study alone.

    ”An innovative new drug can prevent heart attacks and strokes by cutting bad cholesterol to unprecedented levels, say doctors. ”

    Really? I mean who get the yellow envelops to say stuff like that?

    Reply
    1. Andy S

      ”An innovative new drug can CAUSE heart attacks and strokes by cutting AN ESSENTIAL REPAIR MOLECULE to unprecedented levels, say doctors. ”

      Reply
      1. Bill

        Andy
        You are assuming that there is such a think as ‘bad’ cholesterol. Since cholesterol lowering has achieved nothing except contribute to the tidal wave of bad health we seemed to be mired in right now I fail to see the efficacy of it. I think Malcolm and his colleagues at THINCS have done a good job, over the years, in debunking the whole hypothesis (for a hypothesis it is). The current academic and medical view seems me to be based on a skewed correlation ( Keys et el) from which a giant house of cards has been erected, billions of dollars have been made and no causation has ever been properly proven, witness the subject of this article we are currently discussing. We seem to be operating in a world where correlation determines policy. Modern ‘evidence’ based medicine is a sham. The gold standard RCT method is corrupted since the outcome of the RCT seems more often than not to comply with what the sponsor wanted. Much time and effort is being put into propping up a deeply flawed system. Scientists should re- read or maybe read their Popper on the scientific method.

  8. Gary Rees

    An acquaintance recently had a heart attack and was treated with a quadruple bypass . 58 years old. He has recovered nicely and seemed happy that his doctor told him that his cholesterol was good! As a physician how many times would you have to see the paradox to realize that the hypothesis is wrong.
    Also he was an auto mechanic working in garages with less than perfect ventilation for 40 years.
    CO may be the culprit.

    Reply
  9. Mr Chris

    Dear Dr Kendrick
    So Amgen investors were right to mark the shares down after this report, but it might put a nail in cholesterol /heart disease theory, since lower LDL doesn’t do anything for your life expectancy, maybe even the opposite.
    As for Pfizer, since you like scenarios, try this one:
    Boss: this looks like a lousy trial
    Employee: no its very good, the results show very low cholesterol.
    Boss: but people don’t seem to live longer, whats the sense in having a drug that does that if the patients don’t live long enough to continue taking it?
    Have a well deserved break.

    Reply
  10. bobniland

    On the bococizumab:
    http://www.nejm.org/doi/full/10.1056/NEJMoa1701488
    “…trials of PCSK9 inhibition with bococizumab were terminated early by the sponsor owing to the development of antidrug antibodies in other studies in the program.”

    Apparently some 48% of subjects had immune systems that were less than thrilled about monoclonal mouse bits floating around.

    The unfortunate thing about these trials is that Repatha lowers Lp(a). For people with Lp(a), and who are doing diet/supplement/lifestyle interventions that otherwise lower CVD risk, this effect might have net benefit, but are we ever going to get clarity on that?

    Reply
  11. Antony Sanderson

    It is indisputable that statins play a much greater part in cell biochemistry than just stopping the synthesis of cholesterol in the liver cells. They can damage muscle cells leading to painful myopathy (grumble grumble), damage pancreatic cells (more grumbles) and . . . the can interfere with insulin signalling leading to insulin resistance (deafening grumbles). A common side effect of statins is short term memory problems . . . Having found a study that described how insulin was required in the brain in the processing of short term memory, it said to me that it would not be surprising if statin’s ability to promote insulin resistance was to blame. There are other possibilities; however, the point is: we should be very careful when targeting one element of our body biochemistry that it is not usefully involved elsewhere.

    When I first read about PCSK9 inhibitors, like Dr K I thought “so what” . . . but then groaned when I did a little research and found that a reported side effect was short term memory loss. “Oh no not again” . . . . Further research: the brain produces PCSK9 . . . so why does it seem to be a good idea to get rid of it. Where is the risk assessment for lowering PCSK9 in the brain? Further research (today) . . . “the role of PCSK9 in the brain is controversial” . . . Well, that is a surprise.

    Reply
    1. Andy S

      Antony:Does not take much googling to discover problems with statins. The worst impact could be on bone derived progenitor cells used for repair of all tissue types. Result would be ageing cells without chance of replacement . Accelerated ageing.
      “The exact mechanism of action of PCSK9 is not clear, although it is known to enhance the intracellular degradation of the low density lipoprotein (LDL) receptor” All that the researchers saw was LDL.

      Reply
      1. Antony Sanderson

        Andy . . .I go with the accelerated ageing. My wife called the statins ‘your old man pills’. She saw the effect they had on me the longer I took statins and marvelled at the return to (relative) youth when I stopped.

  12. dearieme

    Nicola Harley in the Telegraph related the usual “Scientists say …” guff, and quoted some vainglory from a Professor Sever of Imperial College. Happily she also wrote “the findings … revealed that the drug had no impact on the rate of cardiovascular mortality.”

    And yet it reduced cholesterol by gazillions of percent. You might almost wonder whether the lipid hypothesis is, to some degree or another, false. As in fake. As in bollocks. Still, it’s a livin’, eh?

    Happy hols, doc.

    Reply
  13. mikecawdery

    Re the Evolocumab trial
    Examining the Table 2 w.r.t. actual cause of deaths (as distinct from an addition of several fatal and non-fatal categories) it is obvious that benefits are trivial and not significant. The enthusiastic claims are an example of over enthusiastic astroturfing and agnotology. Money and status win again over lives of patients.

    Reply
  14. ellifeld

    What’s terribly sad is that most people just read the headlines and that doctors will have no problem prescribing this even with this data right in front of them!

    Reply
  15. Sasha

    A friend was telling me recently about NLP techniques. One of the most basic ones – you give fact, fact, fact, INFORMATION (something you’re trying to sell or convince someone of). That BBC release sounds like something out of NLP playbook…

    Reply
  16. Janet B.

    Thank Goodness for the wonderful honest Doctors like yourself Dr. Kendrick ! My Doctor tried to convince me to go on these drugs.I simply said no thanks. It is difficult at best to make that kind of decision always wondering if you just added another nail in your own coffin. Presenting the information in easier to understand “language” allowing us to weigh the data and make an informed decision for ourselves is a gift all of the physicians like yourself give us. Your work is appreciated more than you know !!

    Reply
  17. Gary Ogden

    robert lipp: Berberine was probably their starting point, what gave them the idea. Clearly a doomed drug, as was Pfizer’s. Pharma is getting desperate to keep the profit stream going to keep investors happy, while the public is becoming more aware of how worthless and dangerous many of their products are.

    Reply
  18. Paul Ellis

    Having read the authors’ paper on the Repatha FOURIER trial, it appears that the randomisation between drug and placebo was performed on a regional basis. It would therefore be interesting to see the results by region, since medical standards are likely to vary from one region to another. The four regions were NA (16.6% of patients), Europe (62.9%), Latin America (6.6%) and “Asia Pacific and South Africa” (13.9%).

    Reply
  19. Eliot

    Thanks for doing this report before going on holiday Dr K. To me it looks like another failure in the lipid theory of CVD.

    Reply
  20. Stephen T

    How many wonder drugs are publicised each week in the media? My eyes roll when I read about yet another ‘game changing’ cancer drug. Patients are cajoled by pharma in to demanding the new, expensive drug with miniscule ‘benefits’ and no talk about damaging side effects.

    I doubt there is much true consent in the NHS when it comes to statins, chemotherapy or much else. We get one side of the story and it’s always the side that sells drugs.

    Reply
  21. Andy S

    Patients who follow doctor’s recommendation to lower badLDL PCSK9- inhibitor is probably a better choice than statins. Shotgun approach by interfering with mevalonate pathway causes too much collateral damage. Hopefully the inhibitor will only increase LDL receptors without altering some other cellular function.
    Question is, what is effect on cell being stuffed full of cholesterol.

    Reply
    1. David Bailey

      Surely the shortcomings of statins are well known, so if you swap to a PCSK9 inhibitor you are swapping a known harm for an unknown harm. If I believed in treating cholesterol levels (which I don’t any more), I would at least want to know that my cholesterol was not going to be lowered excessively – it isn’t a poison to be driven from the body!

      Reply
  22. Jean Humphreys

    Thanks for some more solid information to add to my armoury of arguements.
    Oh, and have a good rest – we shall endeavour to survive while you take a well earned break.

    Reply
    1. Andy S

      Jean, I am suffering withdrawal symptoms. Being in Florida for another 2 weeks gives me lots of time to read and relax. Reading Dr. K’s old blogs and letting thoughts incubate.

      Reply
  23. puffball

    “.. we’ve seen cholesterol levels lower than we have ever seen before in the practice of medicine”

    Just why is that a good thing? Lower than all the extremely healthy people who have lived long, happy lives? Lower than all those who have hypocholesterolaemia?

    Wouldn’t we expect a good outcome for cholesterol levels to be somewhere around what generally healthy people have?

    Reply
  24. Kay

    Good Lord, deliver us!
    Thank you for posting this. Have a great holiday. Stay healthy and forget all about this nonsense.

    Reply
  25. JanB

    And why not just let our bodies get on with what they do best. Since my cessation of statins my cholesterol levels have gone up high. – relatively – HDL 3.4, LDL 3.4 and my trigs down to .05, not that it ever that much higher. (My diabetic nurse is practically having kittens at every appointment. Ho ho. As I understand it LDL is an essential part of the immune system and needs to be fairly high. I haven’t had a cold or even a sore throats since I stopped the vile treatment AND my HbA1c plummeted. By the way, I’m old so I NEED my cholesterol, thank you very much.
    Hey, Doctor K, have a great holiday. You deserve it. ☀️☀️☀️

    Reply
    1. Antony Sanderson

      JanB . . . I’d kill for an HDL of 3.4 . . . to me it shows the cholesterol regulation system is spot on. And the low TGs . . . wow . . . I am led to understand that low TG levels indicate low, in your case vanishingly low, numbers of small sized LDL particles, thought by many to be an issue in cardiovascular heath. Speaking as a punter in all this, you seem to be in a very good place.

      Reply
      1. JanB

        Hi Anthony – I put it all down to the fact that I have a very low carb diet to keep my blood sugars in check. No bread, no rice, no roots, no pasta, no sugar, almost no fruit except berries. You know the sort of thing. But, my word, I eat good eggs, cheese and fatty meat prodigiously and like to keep a pot of clotted cream in the fridge for a spoonful every time I pass. I’m really skinny, by the way, AND I love my green vegetables.
        I eat really well, but I only eat REAL FOOD.
        Cheers.

  26. Jennifer.

    Thanks Dr Kendrick…..I was waiting for your reaction to the BBC and all the other distorted accounts of this wonder drug. I am pleased you have found time to comment before scooting off on a well earned holiday.

    Reply
  27. Gail Turner.

    Thanks for another well presented heads up Dr.Kendrick.I have a ( healthy ratios) high cholesterol and can now dodge attempts to entice me onto this drug.I continue to refuse the cholesterol lowering drugs as the legitimate science does not support them.I love my levels,my body would not nuture my cholesterol production and storage if I did not require it is my standpoint.I continue to marvel at the enthusiasm of the industry and its incentivised fan base to dump frankenscience on the public,nor the creativity with which editing of findings is conducted.

    Reply
  28. Martin Back

    “LDL-lowering potency varies between agents. Cerivastatin is the most potent, (withdrawn from the market in August, 2001 due to risk of serious rhabdomyolysis)”https://en.wikipedia.org/wiki/Statin

    Rhabdomyolysis is a condition in which damaged skeletal muscle breaks down rapidly. Perhaps the ultra-low LDL levels achievable with PCSK9 inhibitors make rhabdomyolysis more likely as a side-effect?

    Reply
    1. Eliot

      I am waiting for them to invent a drug that lowers LDL to zero.

      “Good news – no heart attacks in the treatment group.”
      “Bad news – they are all dead.”

      Reply
  29. Andy S

    “The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, indicates that bococizumab is not likely to provide value to patients, physicians, or shareholders,” the company explained.”

    INTERPRETATION:
    – “clinical information” LDL PCSK9- inhibitors kill people who use the drug
    – “evolving treatment” ie LCHF diet, avoiding LDL reducing medications
    – “market landscape” ie sales of statins is declining,
    -provide no value to patients, physicians or shareholders. Writing on the wall: LDL hypothesis is ready to crash

    Reply
  30. Ian Partington

    What are the British Heart Foundation on? Statins? Cholesterol lowering drugs? Or huge bungs from Big Pharma? Let’s hope they wake up and smell the (bullet proof) coffee one day soon!

    Reply
    1. mikecawdery

      They take down evidence that contradicts their support for statins

      Estimated lowest mortality rates for TC blood levels
      All Cause mortality 222 mg/dl 5.75 mmol/L
      Non-communicable disease 210 mg/dl 5.49 mmol/L
      Cardiac Disease 208 mg/dl 5.44 mmol/L
      http://www.heartstats.org/documents/download.asp?nodeib=6797 This URL no longer exists? WHY?
      Now on https://renegadewellness.files.wordpress.com/2011/02/cholesterol-mortality-chart.pdf
      http://healthcorrelator.blogspot.co.uk/2009/12/total-cholesterol-and-cardiovascular.html

      Reply
  31. Mark Johnson

    I thought that manipulation of trial duration, primary end points etc had been outlawed in the early 2000s?

    Reply
  32. JMarcus

    I’m confused about the data. Here’s what was reported in the New York Times, which I am having trouble squaring with the figures reported in Dr. K’s piece: “Participants in the study who used Amgen’s drug for 2.2 years were 20 percent less likely to die from heart disease, have a heart attack or have a stroke (816 patients taking evolocumab had one of those outcomes, compared with 1,013 taking the placebo).
    There was a 15 percent reduction in the combined risk of having a heart attack or stroke or dying from cardiovascular disease, being hospitalized for worsening chest pain, or having a stent inserted to open a blocked artery (1,344 evolocumab patients versus 1,563 placebo patients).
    The absolute reduction in the risk of a heart attack or stroke was 1.3 percent at two years, Amgen said, and 2 percent at three years.”

    Can someone enlighten me on this?

    Reply
    1. mikecawdery

      Jmarcus

      Amgen’s drug for 2.2 years were 20 percent less likely to die from heart disease,
      Downlooad the paper and in Table 2 you will find:

      Evolocumab Placebo Hazard Ratio
      (N = 13,784) (N = 13,780) (95% CI) P Value*
      Cardiovascular
      death 251 (1.8) 240 (1.7) 1.05 (0.88–1.25) 0.62
      Death from
      any cause 444 (3.2) 426 (3.1)
      If you can demonstrate a 20% less from any of those death numbers I would like to know how they did.
      You are right to question the report – Fake News – The NYT is great at fake news

      Reply
      1. Gary Ogden

        mikecawdery: How right you are. A drug that kills folks faster than placebo is a “wonder drug” only in the Orwellian world in which we live. Only if the objective is population reduction. Thank goodness most people still have functioning brains capable of discerning BS when it is dished out by the authorities. Here in the U.S. the media has been the willing servant of the CIA since about 1947. All fake news all the time (except the comics, puzzles, obituaries, and sports scores). Carl Bernstein’s 1976 Rolling Stone article explains how they have carried it out.

      2. Andy S

        A “wonder drug”? “wonder” can have several meanings The “wonder” is why do doctors prescribe these drugs.

      1. Old fogey

        Yes, the “failing NYT” did its best to encourage the public to demand the newest and exceedingly expensive drug from their doctors and their insurers.

        I am no longer amazed or even sickened by such reporting – it has become the new reality. By the way, American magazines geared to women are nowadays full of ads for prescription drugs.

      2. Eliot

        Wait, what?

        They stopped it after two years instead of four because the event rate was 50% higher than expected?

        “Although the median follow-up period
        in FOURIER was originally planned to be approxi-
        mately 4 years, an event rate that was approxi-
        mately 50% higher than had been postulated
        led to a shorter required duration of follow-up to
        accrue the prespecified number of events.”

    2. Martin Back

      When they say “reduction in the combined risk” I think they are talking about the risk factors like cholesterol levels, trig levels etc. which they use to predict disease (i.o.w. surrogate endpoints), but which are not the same as actual deaths, heart attacks etc.

      So if you are treating the numbers, these drugs are fantastic. If you are treating the disease, eh, not so much.

      Reply
  33. Jaide

    Interesting! They are trying to make drugs that kill bad cholesterol but they don’t even know what is this ‘bad cholesterol’ and why do we have it in our bodies! Paradox, huh!

    Reply
    1. Andy S

      HI JAIDE; The average consumer and doctor knows the meaning of “bad”. Therefore killing “bad” cholesterol is “good”. No need to look further.

      Reply
  34. Den Miller

    I’m just a dumb musician – I can only count to 4! Even so, I saw straight through it. 444 deaths vs 426 on placebo. It’s really NOT hard at all to look at the figures critically. What on earth was the BBC correspondent doing to provide a balanced view?

    Reply
  35. Olga Collins

    And hot on the heals of the other post is this one.

    On Mon, Mar 20, 2017 at 6:40 AM, Dr. Malcolm Kendrick wrote:

    > Dr. Malcolm Kendrick posted: “Repatha Just before I head off on holiday > for a couple of weeks, I thought I should make a quick comment on the > Repatha trial (PCSK9- inhibitor). I have written much about this new class > of cholesterol lowering drugs, and I have been highly skeptical t” >

    Reply
  36. Stephen T

    Today’s Times had a good column by Dr Mark Porter on statins, PCSK9 inhibitors and how poor they are in changing real outcomes in comparison to the Mediterranean diet and lifestyle changes.

    Interestingly, the NNT for statins was given as 400! Yes, one in 400 patients might benefit fractionally from statins, if you don’t include the side effects. How many patients are told this? I doubt many people are giving true consent for these supposedly preventative drugs because they’re only getting the pharma half of the story.

    The NNT for blood pressure medication was given as 110.

    You can see the start of the article here, but most of it is behind ‘The Times’ paywall.

    http://www.thetimes.co.uk/article/dr-mark-porter-the-diet-thats-almost-as-good-as-statins-and-im-proof-that-it-works-dj7gstfls29

    Reply
    1. mikecawdery

      This will give Prof. Dr. Sir Rory Collins the opportunity to claim that “ Treat 4,000,000 and save 10,000 lives a year“. I wonder if he will take this wonderful opportunity?

      Reply
    2. mmec7

      Re Times ‘Paywall’. No, there is no paywall, just to register with minimum detail : nameand e-mailaddie. End of. Have just read the full article – he is rather pushing the statin front, or, is gently pushing aside by upping good diet issues. He has an e-mail addie linked to The Times, so I sent him the link to Dr Kendrick’s blog… Others can do likewise…!

      Reply
      1. Stephen T

        Thanks for the advice. I think the tone is very much “Who’d take these if they knew and here’s something better.” But I think he’s a bit cautious to avoid the pharma-funded flack.

  37. mikecawdery

    Dr Kendrick

    Have a great holiday and come back fully refreshed to continue highlighting Big Pharma/ medical industry money-making drugs.

    Reply
  38. bfhu

    What on earth are the statin and PCSK9-inhibitor drugs thinking. If these things cause muscle wasting or problems for muscles? THE HEART IS A MUSCLE!

    Reply
    1. dearieme

      I once objected to a statin-recommending GP that they were notorious for weakening muscles. He reluctantly agreed. I said “the heart is a muscle”. He said that that was quite different. Ain’t science wonderful?

      Reply
  39. Andy S

    Dr. K, Maybe it is time for a new book updating us on the war against cholesterol. Suggested title : THE GREAT WAR-2017
    chapter 1- why cholesterol is bad (for rabbits)
    chapter 2- the final battle, bad cholesterol reduced by 60%, only 40% to go, victory is near
    chapter 3- life without bad cholesterol, technology can replace it with good cholesterol
    chapter 4- saturated fat is bad too, increases bad cholesterol, (the eastern front)
    chapter 5- who are the rebels supporting the enemy?
    chapter 6- why are patients joining the rebels?
    chapter 7- Big Pharma, scientists and most doctors pledge to fight to the end
    chapter 8- aftermath, end of patients

    Reply
    1. David Bailey

      Andy, I love your chapter headings, but I think your title is a bit too close to the bone!

      I’d like to add a few extra chapters, to be merged in as you see fit:

      Chapter ? False recovery syndrome – why some diabetes patients seem to improve with false treatments

      Chapter ? False diets – why some unapproved diets can seem to make you well – how to avoid being fooled.

      Chapter ? Are those who refuse modern cholesterol lowering treatment really sane – the case for forced treatment.

      Chapter ? The heart warming story of a man who refused to let his cholesterol win – even though that put him in a wheel chair.

      Chapter ? How YOU can help charities help Big Pharma!

      Chapter ? Stamping out false medical advice on the internet – the internet petition.

      Reply
      1. Andy S

        David: Agree with comment re title, 100 years is not that long ago.. Another title could be THE 100 YEAR WAR ON BAD CHOLESTEROL. The fight is real and lives are at stake. Poking fun at the opposition could be effective. Your additional chapters are good. The literary critics might consider the book as fiction.

      2. Andy S

        David: The patient has to be educated. The book could be the basis of a TV series if written as a thriller based on real events. The names could be changed to protect the guilty to avoid lawsuits. TV is where average people get educated. There is nothing else that is currently available to bring the cholesterol message to the masses. How many books does the average person read? A TV series with real actors could run for many years (research is evolving) and could rival the Dr. OZ show. Personally I have lost interest in OZ, he was OK in the beginning but now is geared towards a female audience. Also he believes saturated fat is bad.

    2. Christopher Palmer

      Rabbits are okay with cholesterol. It was a small number of the 49 alternate cholesterol oxides that did for them. The fact would do well for being incorporated into chapter 1.

      Reply
  40. Andy S

    Science News
    from research organizations

    Researchers study a new way to lower LDL cholesterol
    Date: March 6, 2017

    Source: Saint Louis University Medical Center

    Summary:
    Drugs targeting a nuclear receptor may be able to lower LDL (bad) cholesterol in an animal model, new findings suggest.

    In a paper published in Biochemical Pharmacology, Saint Louis University researchers examined the way a nuclear receptor called REV-ERB is involved in regulating cholesterol metabolism. Their findings suggest that drugs targeting this nuclear receptor may be able to lower LDL (bad) cholesterol in an animal model.

    Reply
    1. Andy S

      The previous post is a word for word copy of latest news about (bad) LDL.from Science News.
      Note the focus on “(bad)” and “drugs”. Motivation is money, What is the point of doing research?
      If the researchers had read Dr.K’s books and followed discussions on this blog they would have learned not to associate “bad” with LDL. Is any university doing studies of the benefits of cholesterol?
      The war on “(bad) LDL cholesterol” continues.

      Reply
  41. Eric

    This is from Chris Masterjohn episode 16 (on familial hypercholesterema):
    “Polyunsaturated fatty acids also will increase the LDL receptor, because they are more effectively esterified to cholesterol in the liver than other fats, and so if the cholesterol in the liver becomes esterified, the pool of free cholesterol declines, that increases the liver’s sense that it needs more cholesterol, increases the LDL receptor, decreases blood cholesterol – everything down from esterifying the cholesterol is very similar to what statins are doing. But the overall effect is just to move cholesterol from the blood into other compartments such as the liver, and you don’t promote the utilization of that cholesterol. So it’s not like thyroid hormone, where you’re taking cholesterol in from the blood and then you’re doing something with it because you’re ramping up the metabolic rate; you’re just basically stuffing cholesterol into those tissues, and it’s not clear that that’s ideal. ”

    I think he mispoke about PUFA being esterified to cholesterol, maybe he meant that they promote esterification of cholesterol? Anyway, he’s making the point that stuffing cholesterol into the cells cannot be good.

    Reply
    1. mikecawdery

      Statins are also carcinogenic
      Cancer. 1984 May 15;53(10):2034-40.
      The detection of environmental mutagens and potential carcinogens.
      Ames BN.
      PMID: 6367933 [PubMed – indexed for MEDLINE]

      Am J Clin Nutr. 2001 Dec;74(6):714-22.
      gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention.
      Millionaires Keep It for Themselves (MGID)
      Jiang Q1, Christen S, Shigenaga MK, Ames BN.

      The detection of environmental mutagens and potential carcinogens.
      Ames BN.
      Cancer. 1984 May 15;53(10):2034-40. Review. No abstract available.
      PMID: 6367933 [PubMed – indexed for MEDLINE]

      Reply
    2. Gary Ogden

      Randall: According to this meta-analysis, the higher the percent LDL is lowered the higher the risk of developing new-onset diabetes. This new wonder drug, then, should dramatically increase the risk.

      Reply
  42. Dr. Göran Sjöberg

    How many times must we state that there is no “bad cholesterol”?

    There is just one cholesterol chemical molecule and it is “good” for us.

    “Bad cholesterol” is a typical “fake news” and well over fifty years old by now.

    Reply
    1. Mr Chris

      Göran
      Each time I see the words ” bad cholesterol” I shudder.
      My body has a system for regulating my cholesterol levels, if I eat foods containing it, my body produces less, so it seems to know what I need.
      I let it get on with it.

      Reply
  43. Stergio

    I took statins for over 20 years. During this time both my parents died of heart disease despite them taking statins et al. I developed unstable angina 4 years ago and have one stent. I have deliberated over whether to continue or not with them. Dr K, and others, have helped me make my mind up to discontinue them.

    It is my sole responsibility. I now take Vit c, K2, magnesium and carnetine.

    One factor that always troubled my was me being told by my GP I was ‘high risk’ and be I’d be a fool to discontinue statins. I was high risk because of the angina, the stent and my family history of heart disease. I agonised over this ‘high risk’ status for a long time.

    When, through further agonising, even though I’ve stopped taking them, I realised I may not have a ‘family history of heart disease’ rather a ‘family history of taking statins, bp lowering drugs and antacid medication’. It is a thought that gives me comfort.

    Reply
    1. David Bailey

      I hope this decision works out well for you.

      I know a man whose wife was very ill with cancer for a protracted period. He developed some sort of heart murmur and was on a variety of drugs. Some time after she died, he went on holiday, and discovered he had forgotten to take his tablets. He decided to cross his fingers, and by the end of the holiday he felt so much better that he has given up all his medication! His heart problem has not recurred. He came to the conclusion that the stress of his wife’s disease had caused his heart problem, and since then he had healed.

      Have you managed to shed any statin side-effects?

      Reply
  44. Andy S

    Final analysis of Repatha trial (PCSK9- inhibitor).
    – Hypothesis: PCSK9 controls LDL receptor numbers by inhibiting breakdown of LDL receptors
    – Results: Liver cells forced to accept more LDL, patients died
    – Conclusion: LDL should stay in the bloodstream where nature intended it to be
    – What went wrong? Everyone knows that LDL-C is bad. New drugs are in development.

    Reply
    1. JanB

      You hit the nail on the head, Andy S. Surely those with familial hypercholesterolaemia (spelling ?) lack LDL receptors which is why it can be so harmful. Why would big medicine/pharma want to replicate this situation In otherwise healthy people? Maybe I’m missing something here.

      Reply
  45. mikecawdery

    http://bmjopen.bmj.com/content/7/3/e013650?cpetoc
    Global cardiovascular risk assessment in the primary prevention of cardiovascular disease in adults: systematic review of systematic reviews
    Conclusion
    The quality of existing systematic reviews was generally poor and there is currently no evidence reported in these reviews that the prospective use of global cardiovascular risk assessment translates to reductions in CVD morbidity or mortality. There are reductions in SBP, cholesterol and smoking but they may not be clinically significant given their small effect size and short duration. Resources need to be directed to conduct high-quality systematic reviews focusing on hard patient outcomes, and likely further primary RCTs.

    There you have it. Medical reviews are of poor quality!

    Reply
    1. Andy S

      mikecawdrey, the assumption is that if you are the average person (based on the number of people sampled) the risk assessment will be applicable. We are all different, am I an average person? I am starting to suspect that most people are sick (blood pressure, hyperglycemia,overweight, CVD, etc.), there are no healthy people available for a control group.

      Reply
    1. Martin Back

      You have to be so damn careful with statistics. Here is another example regarding false positives I read in a book called “The Drunkard’s Walk”. The writer, physicist Leonard Mlodinow, was refused life insurance on the basis of a medical exam.

      He called his doctor, who told him “As a result of your blood test, the chances are 999 out of a thousand you will be dead in five years.” The test showed he had AIDS, and the false positive rate for that test was 1/1,000. This was in 1982 when AIDS was a death sentence.

      Being statistically knowledgeable, the writer realised his chance of not having AIDS was much better than 1/1,000, because he belonged to a low-risk group, namely monogamous heterosexual men, where the prevalence of AIDS was about 1/10,000. If 10,000 of his group were to be tested, they would throw up ten false positives and one real positive. So his chance of having AIDS on the basis of a positive test was actually only 1/11. (It turned out he had a rare genetic mutation that triggered the test.)

      However, if he had been a drug-using homosexual where the prevalence of AIDS was 1%, if 1,000 of his group were tested they would throw up ten real positives and one false positive. So his chance of having AIDS on the basis of a positive test would be almost a certainty at 10/11.

      As he says, it is vitally important to know the prevalence of whatever is being tested in the sample population, as well as the accuracy of the test.

      Reply
  46. Eric

    Again, off topic, but interesting:
    http://science.sciencemag.org/content/355/6331/1330.full

    Accorning to this, about 2/3 of cancers due to random mutations, 30% environment, 5% genetic. I have only read the abstract so far, and an article in a general magazine summarizing this paper. I think what they are missing is that in additon to carcinogens such as cigarette smoke that actively cause mutations, there are also behavorial or environmental factors that decide whether a tumor gets to grow rapidly or not. Sugar intake, lack of vitamin D and excess DHA from fish oil come to mind. DHA is particularly interesting as it promotes angiogenesis and has been shown to cause AMD (age related macula degeneration) and prostrate cancer by promoting the growth of capillary blood vessels.

    Reply
    1. Andy S

      Eric, this blog is about CVD, but cancer and every other disease could have common causes, you have started a list. My list includes PUFA, linoleic acid is big.

      Reply
  47. Andy S

    Where did AMGEN go wrong? Theory seemed simple enough, more LDL receptors = less LDL = less CVD
    – First: 27,0000 people were too many to test. On the average people do not die that quickly.
    – They should have studied say 100 people but measure and studied as many parameters as possible besides (bad)LDL.
    – Question that should have been answered before testing on 27,000 people: What will the extra LDL particles do to liver cells and any other cell? Will the cells be stressed and cry for help, measure cell response.
    – Do not try to fool Mother Nature.

    Reply
    1. Andy S

      Another hypothesis is needed to explain the failed AMGEN trial.
      1- Cholesterol hypothesis (LDL-C as cause of CVD) is dead
      2- Particle number hypothesis (LDL-P) is emerging. Too many LDL particles cause CVD. Test is not available in Canada. Seems plausible but not convinced that the LDL-P can explain anything.
      3- A new LDL-PQ hypothesis ( LDL particles number and quality). This new hypothesis will not explain everything about CVD, nothing will, but it can explain a lot.. This explanation of the new hypothesis is for the benefit of the average patient. To comprehend the LDL-PQ hypothesis, one must understand the good/bad classification of LDL particles covered in a previous post.

      Why trial failed: more LDL receptors removed LDL (the good cholesterol that cells need) and left only sdLDL (the bad cholesterol) that cannot be used by cells and is not readily taken up. sdLDL sits in the bloodstream and gets glycated and oxidized, and is removed by macrophages to produce foam cells (the beginning of plaque). A cell is literally starved to death. Too many dead cells > dead tissues> dead organs > dead patients.

      This new hypothesis can also be used to explain why statins are harmful, increases number of (bad) sdLDL particles, decreased number of (good) LDL particles. Same concept as in failed AMGEN trial. EASY!

      But statins are good because inflammation is reduced and CVD is an inflammatory disease! True but buggering up body’s defence system is not good except in some cases like heart and liver transplants required because of statin use.

      LESSON: every failure can be a learning experience.

      Reply
      1. Mr Chris

        David Bailey
        There are two answers to your question:
        1 we as a species get wiser/clevejrer all the time
        2 my preferencej is that these things in the absence of real understanding, are fashions, or modes of thinking, so try to reach your own conclusion

      2. Andy S

        David Bailey: Excellent question. An (outdated)hypothesis in a group situation will persist due to peer pressure, job security, loss of confidence in the organization, or financial reasons, even when emerging new information has debunked the hypothesis. This has nothing to do with “belief”. If I believe that saturated fat causes CVD and then a new hypothesis says that sugar causes CVD, I have to make a decision. Why I believed the first hypothesis is now irrelevant. For the sake of my health I have to decide what to “believe”.
        LDL-C is high, you need a statin, or take niacin or…
        LDL-P hypothesis seems plausible, more particles = more chance of particles getting below endothelium. How can I make use of this idea?
        LDL-PQ hypothesis: number of modified lipoprotein particles is the problem. How bad is oxLDL, what can be done to prevent LDL oxidation? Diet is the answer, no medication required.

        Every person has to look after their own health and choose what to believe, and keep asking questions.

  48. Andy S

    Does diet cause CVD?
    How much effect does diet have on CVD? Made a quick summary of what effect diet might have on CVD. Probably affects cancer and dementia as well. Other items like NO are downstream of primary activators. For the use of the average patient there is no need to go into scientific explanations, similar as per car maintenance manual. Something to discuss with doctor before getting a prescription.

    Blood related risk indicators for CVD (derived from blood tests):
    -high TG = from high carb intake > more sdLDL
    -low HDL = from low sat/mono fat intake
    -TG/HDL ratio equivalent to (carb intake)/(fat intake)
    -sdLDL high TG/HDL ratio = more sdLDL= more fatty streaks > plaque, sdLDL affects NO production from endothelial cells
    -high glucose = from high carb diet, > ROS, immune function, endothelial cell dysfunnction
    -high insulin = from high carb diet
    -hs- CRP, inflammation marker, probably effect of high carb intake
    – blood clotting factors (affected by diet?)
    – HbA1c glycated hemoglobin from high blood glucose

    Diet related effect:
    -oxidized cholesterol ( eg powdered eggs in proceeded foods) = foam cells
    -oxidized fats (processed foods, food reparation), inflammatory
    -high PUFA (omega-6 oil, easily oxidized, inflammatory)
    -high carbohydrates (= increased sdLDL), = high insulin & glucose, lower immune function
    – high fructose (a carb but deserves special attention)
    -low sat./mono fat (= low HDL)
    – high protein intake (excess becomes glucose)
    -low micronutrients (minerals & vitamins)
    -heavy metals (lead, mercury etc)
    -plant defence compounds (eg WGA, lectins etc.in wheat)
    -Chemical poisons, (glyphosate, msg, artificial anything)
    – GMO’s

    Medications to improve CVD outcome
    -blood pressure, very little feet on CVD, mostly side effects
    -LDL-C lowering, ie statins, NNT 150? mostly side effects
    -Glucose lowering medications?
    -HDL increasing, not ready for prime time, disaster
    -Inflammation lowering, aspirin
    -Anticoagulants, rat poison
    -plaque roto-rooters

    Reply
  49. chris c

    I can no longer remember who to attribute it to, but a magnificent typo which deserves to be perpetrated

    “cardiovascular morality”

    Reply
  50. AH Notepad

    If people want to lower LDL, and I don’t understand why they should, niacin would do it. The disadvantage is the flush after taking it. The flush can be avoided if niacin (B3) is taken in the form of niacinamide, but then it doesn’t lower cholesterol, though it will probably stop you feeling depressed about it, if you thought you needed to. Dose would be about 3g/day according to the work of Linus Pauling and Abram Hoffer. B3 is also useful in arthritis cases. As with vitamin C, B3 doesn’t have harmful side effects, and it doesn’t earn big pharma any $.

    Reply
  51. mmec7

    Cholesterol: When statins trigger diabetes
    Twenty-five months after the European injunction, this new adverse reaction is not included in the patient’s record for every other case.
    BY JÉRÔME VINCENT
    Published on 22/03/2017 at 11:14 | Point
    http://www.lepoint.fr/sante/cholesterol-quand-les-statines-declenchent-le-diabete-22-03-2017-2113798_40.php

    LA LISTE NOIRE DES MÉDICAMENTS
    Depuis 4 ans, nous dressons la liste des médicaments dont les inconvénients l’emportent sur les bénéfices. Coûteux, ils présentent toujours une alternative et le patient -comme le médecin prescripteur- peuvent s’en dispenser. (THE BLACK LIST OF MEDICINES
    For the past four years, we have been listing medicines whose disadvantages outweigh the benefits. Costly, they always present an alternative and the patient – as the prescribing physician – can dispense with it.) http://www.lepoint.fr/dossiers/sante/liste-noire-des-medicaments/index_2.php
    Twenty-five months after the European injunction, this new adverse reaction is not included in the patient’s record for every other case.
    Statins, which act by decreasing the synthesis of cholesterol and are prescribed to avoid cardiovascular accidents, are the best-selling drug class in the world. More than 6 million French people consume it, and the Health Insurance estimates that they are prescribed to 1 million new patients each year. Beyond the recurring polemics about their interest or uselessness,their undesirable effects on the liver and muscles are
    undeniable. Recently – in 2012 – was recognized a diabetogenic effect by
    European and American drug agencies. From the … (more…paywall)
    ———————————— ##
    Thought might interest –

    Reply

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s